289 results about "Hyperlipemias" patented technology

The invention relates to pediococcus pentosaceus with a cholesterol lowering function and application thereof, and belongs to the technical field of microorganisms. The invention discloses pediococcus pentosaceus with a cholesterol lowering function and application of the pediococcus pentosaceus. The pediococcus pentosaceus R5 (GDMCC No.65659) is separated from special fermented food stinky acid in Guizhou. The in-vitro cholesterol removal rate of the pediococcus pentosaceus R5 can reach 59%, and the pediococcus pentosaceus R5 has the characteristics of acid / cholate resistance, no hemolysis and sensitivity to common antibiotics; an in-vivo lipid-lowering experiment is carried out on a hyperlipidemia model mouse, and the result shows that the strain R5 can remarkably improve the in-vivo dyslipidemia state of the mouse, reduce liver fat accumulation and protect the liver at the same time, and can be used for developing lipid-lowering related probiotic functional products. The strain R5 provided by the invention provides a natural and safe probiotic for preventing and / or treating hyperlipemia.

The invention discloses a steroid compound as well as a preparation method and application thereof. The invention specifically discloses a steroid compound with a structure as shown in a formula I and the like or a pharmaceutically acceptable salt of the steroid compound. The compound provided by the invention has SREBP pathway inhibitory activity, and can be used for preventing and / or treating obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, skin injury and other diseases. # imgabs0 #

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto. (I), (Ia)

The invention provides a pharmaceutical composition containing lactoferrin and application of the pharmaceutical composition in blood fat reduction. Specifically, the KGT-C polypeptide provided by the invention has a very strong effect of reducing the synthesis amount of cholesterol in cells, and after the KGT-C polypeptide is combined with lactoferrin, the generation of cholesterol and LDL can be remarkably reduced, so that the KGT-C polypeptide has a relatively good effect of treating hyperlipidemia.

Disclosed are a steroid compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a use thereof. The compound has SREBP pathway inhibitory activity, and can be used for preventing and / or treating diseases such as obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, and skin injury.

The present disclosure relates to a stable pharmaceutical composition comprising a fixed dose combination of olbistetrapib and ezetimibe or a salt, solvate, or derivative of olbistetrapib and ezetimibe. The disclosure further describes the use of ezetimibe and Eubiquitrapib, for example in such fixed dose combinations, for the preparation of an agent for the treatment of a subject in need of lowering LDL-cholesterol or a subject suffering from hyperlipidemia or mixed dyslipidemia, and methods of treatment for the subject.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia. The traditional Chinese medicine composition comprises the following components: ginseng, lucid ganoderma, safflower, musk, calculus bovis, bear gall, pearl, venenum bufonis, radix aconiti carmichaeli and borneol. According to the traditional Chinese medicine composition disclosed by the invention, through reasonable compatibility of all the components, at least one of indexes such as aorta plaque area, vasomotor inner diameter difference, intima-media thickness, blood fat level, homocysteine content and the like in atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia can be effectively improved; the symptoms of atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia are relieved from multiple aspects, and the progress of the disease course is blocked. The traditional Chinese medicine composition is controllable in quality, convenient for standardized production, safe and reliable in prescription and free of toxic and side effects on human bodies.

The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The invention discloses a polysaccharide composition for treating hyperlipemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing phellinus linteus linteus, inonotus hispidus and boletus coratus and then performing water extraction. The polysaccharide composition provided by the invention can be used for reducing fat vacuolation and fat index, reducing the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increasing the content of high-density lipoprotein cholesterol by inhibiting the increase of weight and blood sugar of a hyperlipidemia mouse; the composition and abundance of intestinal flora are regulated and controlled, the intestinal flora disorder phenomenon is improved, the effect is better than that of single polysaccharide, and a new direction is provided for treatment for assisting blood sugar reduction.

The present disclosure provides diets, treatment regimens and methods of treating and preventing a disease. The diets and treatment regimens comprise depleting one or more nonessential amino acids and adding back protein. Such diets and treatment regimens can be useful in, for example, the treatment of hypercholesterolemia, hyperlipidemia, diabetes, obesity, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or a disease or condition associated therewith.

The invention discloses a lactobacillus rhamnosus Z160 strain and an application of the lactobacillus rhamnosus Z160 strain in preparation of selenium-rich exopolysaccharides. The Z160 strain is separated from fermented pickled Chinese cabbages and is preserved in Guangdong Microbial Culture Collection Center on September 5, 2024, and the preservation number is GDMCC NO: 65104. When the Z160 strain is cultured, the yield of the exopolysaccharide can be increased by adding a selenium source, the obtained exopolysaccharide is high in selenium content and has good antioxidant and cholesterol-reducing activity, the Z160 strain can be used for preparing the selenium-rich exopolysaccharide, and the prepared selenium-rich polysaccharide can also be used for preparing products for preventing and treating hyperlipidemia and prolonging the life of animals. Besides, the selenium-rich exopolysaccharide prepared from the Z160 strain can inhibit formation of biofilms of pathogenic bacteria such as Listeria monocytogenes, and the obtained polysaccharide can be used for preventing and treating diseases related to the biofilms, cleaning and maintaining instruments polluted by the biofilms and the like.

Disclosed in the present invention are steroid compounds, a preparation method therefor and the use thereof. Particularly disclosed are steroid compounds having a structure shown as formula (I), (II) or (III), etc., or pharmaceutically acceptable salts thereof. The compounds provided by the present invention have SREBP pathway inhibitory activity, and thus can be used for preventing and / or treating obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, skin injury and other diseases.

The invention relates to a pharmaceutical composition for treating hyperlipidemia. The invention relates to the field of medicines, in particular to a pharmaceutical composition of probucol and statins, a pharmaceutical composition or a medicine box containing probucol and statins, and application of the pharmaceutical composition, the pharmaceutical composition or the medicine box in preparation of medicines for treating hyperlipidemia, in particular severe hypertriglyceridemia and severe hypercholesteremia, and application of the pharmaceutical composition, the pharmaceutical composition or the medicine box in preparation of medicines for treating hyperlipidemia, in particular severe hypertriglyceridemia and severe hypercholesteremia. The pharmaceutical composition, the pharmaceutical composition containing the probucol and the statins or the medicine box is characterized in that the pharmaceutical composition, the pharmaceutical composition containing the probucol and the statins or the medicine box containing the probucol and the statins contains a small dose of the probucol and the statins, and the probucol and the statins are configured to be in a form of simultaneous administration.

The invention discloses a steroid compound as well as a preparation method and application thereof. The invention specifically discloses a steroid compound with a structure shown as a formula I, II, III or the like or a pharmaceutically acceptable salt of the steroid compound. The compound provided by the invention has SREBP pathway inhibitory activity, and can be used for preventing and / or treating obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, skin injury and other diseases. # imgabs0 #

The invention relates to a compound probiotic for preventing, relieving or treating hyperlipemia. The compound probiotic comprises a Bifidobacterium animalis subsp. Lactis C-2 strain with the preservation number of GDMCC (China General Microbiological Culture Collection Center) No: 65455 and a Lactobacillus fermentum GLF-217 strain with the preservation number of CGMCC No.28336. The invention further relates to a preparation method of the compound probiotic for preventing, relieving or treating the hyperlipemia. The two strains have potential interaction and can cooperate with each other to achieve synergistic interaction, and the effect of preventing, relieving or treating hyperlipemia is remarkably improved through compounding of the two strains. Specifically, the weight and the fat content are obviously reduced, the blood sugar and blood fat level is improved, the immunity is regulated, the antioxidant level is improved, the fat tissue metabolism level is regulated, and the gastrointestinal tract short-chain fatty acid metabolism is improved.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

The present invention relates to the field of traditional Chinese medicine technology, and in particular to a Chinese medicine composition, granule preparation and preparation method thereof for treating carotid atherosclerosis combined with hyperlipidemia. The Chinese medicine composition for treating carotid atherosclerosis combined with hyperlipidemia is mainly prepared from the following components in parts by weight: 8-12 parts of Chuanxiong, 8-12 parts of red peony root, 3-7 parts of coptis root, 8-12 parts of red yeast rice and 3-7 parts of roasted liquorice. The Chinese medicine composition provided by the present invention can have good therapeutic effects on the patient group with carotid atherosclerosis combined with hyperlipidemia, which is a common and frequently occurring disease in the field of cardiovascular disease prevention and treatment. In addition, the present invention prepares the Chinese medicine composition into a granule preparation in a certain manner, ensuring the molding rate, solubility rate, bulk density, angle of repose and moisture absorption rate of the preparation, thereby ensuring the efficacy of the preparation, extending the storage time of the product, taking into account the patient's acceptance, and easily realizing large-scale production.

The invention discloses a highly efficient cholesterol-lowering Lactobacillus paracasei I MAUJBC1 and its application, and relates to the technical field of functional microorganisms. The strain disclosed in the invention can alleviate weight gain caused by a high-fat diet, improve elevated blood lipid levels; reduce the expression level of cholesterol synthesis genes in the liver; significantly increase the expression level of cholesterol metabolism genes in the liver, and play a cholesterol-lowering role; and increase the abundance of beneficial bacteria in the intestinal flora, effectively improve the intestinal flora disorder caused by a high-fat diet, and play a role in alleviating hyperlipidemia.

The invention discloses a glycinin compound for preventing hyperlipemia as well as a preparation method and application of the glycinin compound, and belongs to the field of biological medicines. The preparation method comprises the following steps: stirring and mixing resveratrol and a soybean 7S globulin solution at 40-60 DEG C for 1.5-2.5 h, so that resveratrol and soybean 7S globulin are fully combined to obtain a glycinin compound; the mass ratio of the soybean 7S globulin to the resveratrol is (250: 50)-(250: 45). Experimental results show that the glycinin compound disclosed by the invention can inhibit the weight increase of a hyperlipemia rat, remarkably reduce the fat index and the liver index, effectively improve the abnormal change of the blood fat factor level and show an obvious lipid-lowering effect. In-vitro simulated digestion experiments show that the glycinin compound shows peptide fragments with different strength from soybean 7S protein after gastrointestinal digestion, and meanwhile, the glycinin compound improves the in-vitro cholate binding capacity.

Provided are an isoquinolinone compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a prodrug molecule, and a mixture thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as an FABP4 / FABP5 dual-targeting inhibitor. Related aryl carboxylic acid compounds can be used for preparing drugs for treating metabolic diseases (such as diabetes, insulin resistance, hyperlipidemia, and atherosclerosis), autoimmune diseases and cancers.

The invention belongs to the technical field of biological medicines, and relates to application of LSR, LncRNA-LSR-AS1 or targeted siRNA in prevention and / or treatment of hyperlipidemia or related diseases thereof. The invention finds that the overexpression of the LSR gene shows a remarkable lipid-lowering effect in various hyperlipidemia models; the long-chain non-coding RNA (LncRNA-LSR-AS1) is specifically combined with a 3 'UTR (Untranslated Region) region of the LSR mRNA to negatively regulate the expression of the LSR gene; the targeting siRNA designed by aiming at the LncRNA-LSR-AS1 can be used for effectively inhibiting the expression of the LncRNA-LSR-AS1 and relieving the inhibiting effect of the LncRNA-LSR-AS1 on the LSR, so that the expression of the LSR is promoted. Effective intervention on hyperlipidemia can be achieved aiming at the target spots, the effects do not depend on an LDLR channel, and unique value is achieved for familial hypercholesterolemia with the poor PCSK9 inhibitor curative effect.

The present invention discloses Jiangzhuo Quyu Granules for treating hyperlipidemia, which is a preparation made from raw medicinal materials in the following weight ratios: 20 - 30 parts of ginseng, 15 - 25 parts of atractylodes macrocephala, 20 - 30 parts of poria cocos, 18 - 22 parts of cuscuta chinensis, 12 - 18 parts of eucommia ulmoides, 10 - 20 parts of dipsacus asperoides, 20 - 30 parts of wolfberry fruit, 15 - 25 parts of safflower, 20 - 30 parts of motherwort, 10 - 20 parts of notoginseng, 10 - 20 parts of cistanche deserticola, 20 - 30 parts of cinnamon, 15 - 25 parts of epimedium, 12 - 18 parts of pinellia ternata, 20 - 30 parts of platycodon grandiflorum, 10 - 20 parts of fritillaria cirrhosa, 20 - 30 parts of sterculia lychnophora, 20 - 30 parts of peucedanum praeruptorum, 15 - 25 parts of mulberry bark, 20 - 30 parts of immature bitter orange, 15 - 25 parts of magnolia officinalis, and also discloses its preparation method and use in the preparation of drugs for treating hyperlipidemia, and the hyperlipidemia is of the phlegm-turbidity obstruction syndrome type.

The present invention relates to use of an anti-ANGPTL3 antibody in treating hyperlipidemia and a method. Specifically, the present invention relates to use of an anti-ANGPTL3 antibody or an antigen-binding fragment thereof in preparing a drug for treating hyperlipemia patients, wherein the hyperlipemia patients are subject to the risk of atherosclerosis cardiovascular disease.

The invention provides vinasse dietary fiber with blood fat reducing activity and a preparation method of the vinasse dietary fiber. The vinasse dietary fiber with relatively high purity is obtained by performing alkali soaking, sodium chlorite bleaching, crushing and drying on the vinasse. The prepared vinasse dietary fiber can effectively improve hyperlipidemia of obese diabetes model mice, reduce triglyceride and total cholesterol levels of serum and liver and improve liver injury, and can be applied to preparation of functional food, health care products, medicines and feeds with the blood glucose reducing effect.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The invention provides a lipid-lowering traditional Chinese medicine composition and extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The lipid-lowering traditional Chinese medicine composition is prepared from the following raw materials: rhizoma cyperi and radix gentianae. The invention further provides an extract of the lipid-lowering traditional Chinese medicine composition. The extract is obtained by mixing rhizoma cyperi and radix gentianae and then co-extracting. The composition or the extract can be used for preparing medicines for preventing and / or treating hyperlipemia, and can be used for improving lipid metabolism disorder of liver cells and reducing the content of triglyceride and total cholesterol in the liver cells.

The present disclosure relates to methods of administering thyroid hormone receptor agonists. The present disclosure provides methods wherein the methods maintain the activity of a given thyroid receptor agonist in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related conditions, meanwhile, thyroid-related and thyroid axis-related side effects are reduced or eliminated.

The invention belongs to the technical field of medicine, and particularly relates to application of northern swertia extract in preparation of medicine for preventing or treating metabolic diseases, the metabolic diseases comprise at least one of obesity and hyperlipidemia, and the northern swertia extract is alcohol extract of northern swertia or is prepared by supercritical CO2 extraction of northern swertia. When the swertia northern extract is used for treating obesity, hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases, the diversity of intestinal flora can be regulated and controlled, the abundance of beneficial bacteria is improved, bile acid metabolism is promoted, and in-vivo lipid metabolism is promoted.